Viral pathophysiology of multiple sclerosis: A role for Epstein-Barr virus infection?

Pathophysiology

Volumn 18, Issue 1, 2011, Pages 13-20

  Maghzi, Amir Hadi ^a,b,c   Marta, Monica ^a   Bosca, Isabel ^a,d   Etemadifar, Masoud ^b,c   Dobson, Ruth ^a   Maggiore, Cosimo ^a   Giovannoni, Gavin ^a   Meier, Ute Christiane ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b Isfahan Research Committee of Multiple Sclerosis (IRCOMS)   (Iran)

^c ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d HOSPITAL UNIVERSITARIO LA FE   (Spain)

Author keywords

B cell; CD8+ T cells; Epstein Barr virus; Infectious mononucleosis; Lymphoma; Multiple sclerosis; Pathophysiology

Indexed keywords

EPSTEIN BARR VIRUS ANTIGEN 1; IMMUNOGLOBULIN G ANTIBODY; LATENT MEMBRANE PROTEIN 1; VIRUS CAPSID ANTIGEN;

ANTIBODY TITER; ARTICLE; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DISEASE ASSOCIATION; EPSTEIN BARR VIRUS INFECTION; GENOTYPE; HUMAN; INFECTIOUS MONONUCLEOSIS; LATENT VIRUS INFECTION; MULTIPLE SCLEROSIS; NEUROIMAGING; NEUROPATHOLOGY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SEROCONVERSION; VIRUS GENOME; VIRUS LOAD; VIRUS PATHOGENESIS; VIRUS REACTIVATION;

EID: 78650543846     PISSN: 09284680     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pathophys.2010.04.003     Document Type: Article

References (71)

1. Lünemann J.D., Kamradt T., Martin R., Münz C. Epstein-barr virus: environmental trigger of multiple sclerosis?. J. Virol. 2007, 81:6777-6784.
2. Thomas R., Macsween K.F., McAulay K., Clutterbuck D., Anderson R., Reid S., Higgins C.D., Swerdlow A.J., Harrison N., Williams H., Crawford D.H. Evidence of shared Epstein-Barr viral isolates between sexual partners, and low level EBV in genital secretions. J. Med. Virol. 2006, 78:1204-1209.
3. Halder S., Murakami M., Verma S.C., Kumar P., Yi F., Robertson E.S. Early events associated with infection of Epstein-Barr virus infection of primary B-cells. PLoS One 2009, 4:e7214.
4. Ascherio A., Munger K.L. Epstein-Barr virus infection and multiple sclerosis: a review. J Neuroimmune Pharmacol 2010, 6.
5. Thorley-Lawson D.A., Gross A. Persistence of the Epstein-Barr virus and the origins of associated lymphomas. N. Engl. J. Med. 2004, 350:1328-1337.
6. Harley JB, James JA. Everyone comes from somewhere: systemic lupus erythrematosus (SLE) and Epstein-Barr virus, induction of host interferon (INF) and humoral anti-ENBA-1 immunity. Arthritis & Rheumatism (2010) [epub].
7. Pohl D. Epstein-Barr virus and multiple sclerosis. J. Neurol. Sci. 2009, 286:62-64.
8. Warner H.B., Carp R.I. Multiple sclerosis and Epstein-Barr virus. Lancet 1981, 2:1290.
9. Haahr S., Höllsberg P. Multiple sclerosis is linked to Epstein-Barr virus infection. Rev. Med. Virol. 2006, 16:297-310.
10. Thacker E.L., Mirzaei F., Ascherio A. Infectious mononucleosis and risk for multiple sclerosis: a meta-analysis. Ann. Neurol. 2006, 59:499-503.
11. Haahr S., Plesner A.M., Vestergaard B.F., Höllsberg P. A role of late Epstein-Barr virus infection in multiple sclerosis. Acta. Neurol. Scand. 2004, 109:270-275.
12. Nielsen T.R., Rostgaard K., Nielsen N.M., Koch-Henriksen N., Haahr S., Sørensen P.S., Hjalgrim H. Multiple sclerosis after infectious mononucleosis. Arch. Neurol. 2007, 64:72-75.
13. Ascherio A., Munch M. Epstein-Barr virus and multiple sclerosis. Epidemiology 2000, 11:220-224.
14. Ascherio A., Munger K.L. Environmental risk factors for multiple sclerosis. Part I: The role of infection. Ann. Neurol. 2007, 61:288-299.
15. L.I. Levin, K.L. Munger, E.J. O'Reilly, K.I. Falk, A. Ascheri, Primary infection with the Epstein-Barr virus and risk of multiple sclerosis, Ann. Neurol., 2010, in press. doi:10.1002/ana.21978.
16. Pohl D., Krone B., Rostasy K., Kahler E., Brunner E., Lehnert M., et al. High seroprevalence of Epstein-Barr virus in children with multiple sclerosis. Neurology 2006, 67:2063-2065.
17. Banwell B., Krupp L., Kennedy J., et al. Clinical features and viral serologies in children with multiple sclerosis: a multinational observational study. Lancet Neurol. 2007, 6:773-781.
18. Ahorro J.M., Magalhaes S., Teillier R., McGowan M., Arnols D.L., Sadovnick D., Bar-Or A., Banwell B. Comparison of clinical manifestations in EBV-positive and EBV-negative paediatric MS patients. Mult. Scler. 2009, 15:S85.
19. Ascherio A., Munger K.L., Lennette E.T., Spiegelman D., Hernan M.A., Olek M.J., Hankinson S.E., Hunter D.J. Epstein-Barr virus antibodies and risk of multiple sclerosis: a prospective study. JAMA 2001, 286:3083-3088.
20. DeLorenze G.N., Munger K.L., Lennette E.T., Orentreich N., Vogelman J.H., Ascherio A. Epstein-Barr virus and multiple sclerosis: evidence of association from a prospective study with long-term follow-up. Arch. Neurol. 2006, 63:839-844.
21. Levin L.I., Munger K.L., Rubertone M.V., Peck C.A., Lennette E.T., Spiegelman D., Ascherio A. Temporal relationship between elevation of Epstein-Barr virus antibody titers and initial onset of neurological symptoms in multiple sclerosis. JAMA 2005, 293:2496-2500.
22. Sundström P., Juto P., Wadell G., Hallmans G., Svenningsson A., Nyström L., et al. An altered immune response to Epstein-Barr virus in multiple sclerosis: a prospective study. Neurology 2004, 62:2277-2282.
23. Lindsey J., Hatfield L. Epstein-Barr virus neutralising antibodies in multiple sclerosis. Mult. Scler. 2009, 15:S83.
24. Wandinger K., Jabs W., Siekhaus A., et al. Association between clinical disease activity and Epstein-Barr virus reactivation in MS. Neurology 2000, 55:178-184.
25. Buljevac D., van Doornum G.J., Flach H.Z., et al. Epstein-Barr virus and disease activity in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 2005, 76:1377-1381.
26. Farrell R.A., Antony D., Wall G.R., Clark D.A., Fisniku L., Swanton J., Khaleeli Z., Schmierer K., Miller D.H., Giovannoni G. Humoral immune response to EBV in multiple sclerosis is associated with disease activity on MRI. Neurology 2009, 73:32-38.
27. Zivadinov R., Weinstock-Guttman B., Zorzon M., Uxa L., Serafin M., Bosco A., Bratina A., Maggiore C., Grop A., Tommasi M.A., Srinivasaraghavan B., Ramanathan M. Gene-environment interactions between HLA B7/A2, EBV antibodies are associated with MRI injury in multiple sclerosis. J. Neuroimmunol. 2009, 209:123-130.
28. Zivadinov R., Zorzon M., Weinstock-Guttman B., Serafin M., Bosco A., Bratina A., Maggiore C., Grop A., Tommasi M.A., Srinivasaraghavan B., Ramanathan M. Epstein-Barr virus is associated with grey matter atrophy in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 2009, 80:620-625.
29. Hollsberg P., Kusk M., Bech E., et al. Presence of Epstein-Barr virus and human herpesvirus 6B DNA in multiple sclerosis patients: associations with disease activity. Acta. Neurol. Scand. 2005, 112:395-402.
30. Wagner H.J., Munger K.L., Ascherio A. Plasma viral load of Epstein-Barr virus and risk of multiple sclerosis. Eur. J. Neurol. 2004, 11:833-834.
31. Lünemann J.D., Tintoré M., Messmer B., Strowig T., Rovira A., Perkal H., Caballero E., Münz C., Montalban X., Comabella M. Elevated EBNA1 immune responses predict conversion to multiple sclerosis. Ann. Neurol. 2010, 67:159-169.
32. Nielsen T.R., Pedersen M., Rostgaard K., Frisch M., Hjalgrim H. Correlations between Epstein-Barr virus antibody levels and risk factors for multiple sclerosis in healthy individuals. Mult. Scler. 2007, 13:420-423.
33. De Jager P.L., Simon K.C., Munger K.L., et al. Integrating risk factors: HLA-DRB1*1501 and Epstein-Barr virus in multiple sclerosis. Neurology 2008, 70:1113-1118.
34. Sundstrom P., Nystrom L., Jidell E., et al. EBNA-1 reactivity and HLA DRB1*1501 as statistically independent risk factors for multiple sclerosis: a case-control study. Mult. Scler. 2008, 14:1120-1122.
35. Nielsen T., Rostgaard K., Askling J., et al. Effects of infectious mononucleosis and HLA-DRB1*15 in multiple sclerosis. Mult. Scler. 2009, 15:431-436.
36. Munch M., Hvas J., Christensen T., Møller-Larsen A., Haahr S. A single subtype of Epstein-Barr virus in members of multiple sclerosis clusters. Acta. Neurol. Scand. 1998, 98:395-399.
37. Lindsey J.W., Patel S., Zou J. Epstein-Barr virus genotypes in multiple sclerosis. Acta. Neurol. Scand. 2008, 117:141-144.
38. Nemerow G.R., Mold C., Schwend V.K., Tollefson V., Cooper N.R. Identification of gp350 as the viral glycoprotein mediating attachment of Epstein-Barr virus (EBV) to the EBV/C3d receptor of B cells: sequence homology of gp350 and C3 complement fragment C3d. J. Virol. 1987, 61:1416-1420.
39. Wang X., Hutt-Fletcher L.M. Epstein-Barr virus lacking glycoprotein gp42 can bind to B cells but is not able to infect. J. Virol. 1998, 72:158-163.
40. Subklewe M., Paludan C., Tsang M.L., Mahnke K., Steinman R.M., Münz C. Dendritic cells cross-present latency gene products from Epstein-Barr virus-transformed B cells and expand tumor-reactive CD8(+) killer T cells. J. Exp. Med. 2001, 193:405-411.
41. Li L., Liu D., Hutt-Fletcher L., Morgan A., Masucci M.G., Levitsky V. Epstein-Barr virus inhibits the development of dendritic cells by promoting apoptosis of their monocyte precursors in the presence of granulocyte macrophage-colony-stimulating factor and interleukin-4. Blood 2002, 99:3725-3734.
42. Guerreiro-Cacais A.O., Li L., Donati D., Bejarano M.T., Morgan A., Masucci M.G., Fletcher Hutt-L., Levitsky V. Capacity of Epstein-Barr virus to infect monocytes and inhibit their development into dendritic cells is affected by the cell type supporting virus replication. J. Gen. Virol. 2004, 85:2767-2778.
43. Hislop A.D., Taylor G.S., Sauce D., Rickinson A.B. Cellular responses to viral infection in humans: lessons from Epstein-Barr virus. Annu. Rev. Immunol. 2007, 25:587-617.
44. Tan L.C., Gudgeon N., Annels N.E., Hansasuta P., O'Callaghan C.A., Rowland-Jones S., McMichael A.J., Rickinson A.B., Callan M.F. A re-evaluation of the frequency of CD8+ T cells specific for EBV in healthy virus carriers. J. Immunol. 1999, 162:1827-1835.
45. Bornkamm G.W., Behrends U., Mautner J. The infectious kiss: newly infected B cells deliver Epstein-Barr virus to epithelial cells. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:7201-7202.
46. Höllsberg P., Hansen H.J., Haahr S. Altered CD8+ T cell responses to selected Epstein-Barr virus immunodominant epitopes in patients with multiple sclerosis. Clin. Exp. Immunol. 2003, 132:137-143.
47. Gronen F., Ruprecht K., Weissbrich B., Klinker E., Kroner A., Hofstetter H.H., Rieckmann P. Frequency analysis of HLA-B7-restricted Epstein-Barr virus-specific cytotoxic T lymphocytes in patients with multiple sclerosis and healthy controls. J. Neuroimmunol. 2006, 180:185-192.
48. Jilek S., Schluep M., Meylan P., Vingerhoets F., Guignard L., Monney A., Kleeberg J., Le Goff G., Pantaleo G., Du Pasquier R.A. Strong EBV-specific CD8+ T-cell response in patients with early multiple sclerosis. Brain 2008, 131:1712-1721.
49. Pender M.P., Csurhes P.A., Lenarczyk A., Pfluger C.M., Burrows S.R. Decreased T cell reactivity to Epstein-Barr virus infected lymphoblastoid cell lines in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 2009, 80:498-505.
50. Levitskaya J., Oram M., Levitsky V., Imreh S., Steigerwald-Mullen P.M., Klein G., Kurilla M.G., Masucci M.G. Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1. Nature 1995, 375:685-688.
51. Lünemann J.D., Edwards N., Muraro P.A., Hayashi S., Cohen J.I., Münz C., Martin R. Increased frequency and broadened specificity of latent EBV nuclear antigen-1-specific T cells in multiple sclerosis. Brain 2006, 129:1493-1506.
52. Ressing M.E., Horst D., Griffin B.D., Tellam J., Zuo J., Khanna R., Rowe M., Wiertz E.J. Epstein-Barr virus evasion of CD8(+) and CD4(+) T cell immunity via concerted actions of multiple gene products. Semin. Cancer Biol. 2008, 18:397-408.
53. Taylor G.S., Long H.M., Haigh T.A., Larsen M., Brooks J., Rickinson A.B. A role for intercellular antigen transfer in the recognition of EBV-transformed B cell lines by EBV nuclear antigen-specific CD4+ T cells. J. Immunol. 2006, 177:3746-3756.
54. Prineas J. Paramyxovirus-like particles associated with acute demyelination in chronic relapsing multiple sclerosis. Science 1972, 178:760-763.
55. Lewandowski L.J., Lief F.S., Verini M.A., Pienkowski M.M., ter Meulen V., Koprowski H. Analysis of a viral agent isolated from multiple sclerosis brain tissue: characterization as a parainfluenzavirus type 1. J. Virol. 1974, 13:1037-1045.
56. Hayano M., Sung J.H., Mastri A.R. "Paramyxovirus-like" intranuclear inclusions occurring in the nervous system in diverse unrelated conditions. J. Neuropathol. Exp. Neurol. 1976, 35:287-294.
57. Kirk J., Hutchinson W.M. The fine structure of the CNS in multiple sclerosis. I. Interpretation of cytoplasmic papovavirus-like and paramyxovirus-like inclusions. Neuropathol. Appl. Neurobiol. 1978, 4:343-356.
58. Cosby S.L., McQuaid S., Taylor M.J., et al. Examination of eight cases of multiple sclerosis and 56 neurological and non-neurological controls for genomic sequences of measles virus, canine distemper virus, simian virus 5 and rubella virus. J. Gen. Virol. 1989, 70:2027-2036.
59. Godec M.S., Asher D.M., Murray R.S., et al. Absence of measles, mumps, and rubella viral genomic sequences from multiple sclerosis brain tissue by polymerase chain reaction. Ann. Neurol. 1992, 32:401-404.
60. Murray R.S., Brown B., Brian D., Cabirac G.F. Detection of coronavirus RNA and antigen in multiple sclerosis brain. Ann. Neurol. 1992, 31:525-533.
61. Sanders V.J., Waddell A.E., Felisan S.L., Li X., Conrad A.J., Tourtellotte W.W. Herpes simplex virus in postmortem multiple sclerosis brain tissue. Arch. Neurol. 1996, 53:125-133.
62. Sanders V.J., Felisan S., Waddell A., Tourtellotte W.W. Detection of herpesviridae in postmortem multiple sclerosis brain tissue and controls by polymerase chain reaction. J. Neurovirol. 1996, 2:249-258.
63. Reiber H., Ungefehr S., Jacobi C. The intrathecal, polyspecific and oligoclonal immune response in multiple sclerosis. Mult. Scler. 1998, 4:111-117.
64. Allen I., Brankin B. Pathogenesis of multiple sclerosis-the immune diathesis and the role of viruses. J. Neuropathol. Exp. Neurol. 1993, 52:95-105.
65. Hilton D.A., Love S., Fletcher A., Pringle J.H. Absence of Epstein-Barr virus RNA in multiple sclerosis as assessed by in situ hybridization. J. Neurol. Neurosurg. Psychiatry 1994, 57:975-976.
66. Opsahl M.L., Kennedy P.G. An attempt to investigate the presence of Epstein Barr virus in multiple sclerosis and normal control brain tissue. J. Neurol. 2007, 254:425-430.
67. Serafini B., Rosicarelli B., Franciotta D., et al. Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain. J. Exp. Med. 2007, 204:2899-2912.
68. Willis S.N., Stadelmann C., Rodig S.J., et al. Epstein-Barr virus infection is not a characteristic feature of multiple sclerosis brain. Brain 2009, 132:3318-3328.
69. Peferoen L.A., Lamers F., Lodder L.N., Gerritsen W.H., Huitinga I., Melief J., Giovannoni G., Meier U., Hintzen R.Q., Verjans G.M., van Nierop G.P., Vos W., Peferoen-Baert R.M., Middeldorp J.M., van der Valk P., Amor S. Epstein Barr virus is not a characteristic feature in the central nervous system in established multiple sclerosis. Brain 2009, 16.
70. Sargsyan S.A., Shearer A.J., Ritchie A.M., Burgoon M.P., Anderson S., Hemmer B., Stadelmann C., Gattenloehner S., Owens G.P., Gilden D., Bennett J.L. Absence of Epstein-Barr virus in the brain and CSF of patients with multiple sclerosis. Neurology 2010, 74:1127-1135.
71. Tzartos J., Khan G., Vossenkaemper A., Meager T., Sefia E., Clemens M., Giovannoni G., Meier U. The anti-viral cytokine Interferon-alpha is expressed in acute MS lesions and associated with the presence of Epstein-Barr virus infection. Mult. Scler. 2009, 15:S276.